← Back to Search

[68Ga]-Pentixafor Imaging for Blood Cancers

Q: What is the capacity for participants of this experiment?

<p>Affirmative. The information hosted on clinicaltrials.gov reveals that this medical study, which was initially shared on October 1st 2021, is currently seeking volunteers. In total, 20 people are needed from a single centre for the trial to be completed.</p>

Q: Is there room in this research program for additional participants?

<p>Affirmative. Data hosted on clinicaltrials.gov supports the notion that this medical trial, first posted in October 1st 2021, is looking for participants. Specifically it needs 20 patients from a single site to complete its objectives.</p>

Phase < 1

Recruiting

Led By Simone Krebs, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

MGUS/SMM or MM according to IMWG definitions

Histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial is testing a new imaging agent to see how well it works in patients with MGUS, SMM, or NHL.

Who is the study for?

Adults over 18 with certain blood cancers like multiple myeloma, non-Hodgkin's lymphoma, or histiocytic neoplasms can join this trial. It's for MSKCC patients who haven't had treatment yet, those whose treatment didn't work, or if it came back. Women must not be pregnant and everyone should be able to handle a PET/CT scan without issues.Check my eligibility

What is being tested?

[68Ga]-Pentixafor is being tested as an imaging agent in PET/CT scans to see how well it shows up in various blood cancers including multiple myeloma and non-Hodgkin's lymphoma. The study will help understand the distribution of CXCR4 expression in these conditions.See study design

What are the potential side effects?

The side effects are not detailed here but may include reactions related to the injection of [68Ga]-Pentixafor and discomfort from lying still during the PET/CT scan procedure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My condition is diagnosed as MGUS, SMM, or MM.

Select...

I have been diagnosed with a type of histiocytic neoplasm.

Select...

I have a slow-growing type of Non-Hodgkin lymphoma that can be measured.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Tumor standard uptake value (SUV)

Trial Design

1Treatment groups

Experimental Treatment

Group I: [68Ga]-PentixaforExperimental Treatment1 Intervention

An intravenous bolus of 4.1 mCi (150 MBq) ± 10% of [68Ga]-Pentixafor will be injected in all participants that will be imaged on a hybrid PET/CT device. Any of the following factors may determine if imaging cannot be performed: tolerance/compliance in the PET/CT scanner; dose availability; dose quality control; availability of the PET/CT scanner or availability of study personnel. [68Ga]-Pentixafor uptake dynamics / pharmacokinetics will be evaluated by PET/CT performed with a low-dose CT component used for PET attenuation correction (1-2 mSv). [68Ga]-Pentixafor-PET/CT scan duration will be approximately 1.5 hours. Some patients will have two scans.

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,936 Previous Clinical Trials

588,878 Total Patients Enrolled

4 Trials studying Erdheim-Chester Disease

443 Patients Enrolled for Erdheim-Chester Disease

Pentixapharm AGIndustry Sponsor

3 Previous Clinical Trials

164 Total Patients Enrolled

PentixaPharm GmbHIndustry Sponsor

1 Previous Clinical Trials

1 Total Patients Enrolled

Media Library

Erdheim-Chester Disease Clinical Trial 2023: [68Ga]-Pentixafor Highlights & Side Effects. Trial Name: NCT05093335 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the capacity for participants of this experiment?

"Affirmative. The information hosted on clinicaltrials.gov reveals that this medical study, which was initially shared on October 1st 2021, is currently seeking volunteers. In total, 20 people are needed from a single centre for the trial to be completed."

Answered by AI

Is there room in this research program for additional participants?

"Affirmative. Data hosted on clinicaltrials.gov supports the notion that this medical trial, first posted in October 1st 2021, is looking for participants. Specifically it needs 20 patients from a single site to complete its objectives."

Answered by AI